Skip to main content

Table 2 Drug sensitivity IC50-values and Relative resistance

From: Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines

Anti- cancer drugs

Epirubicin

RR

Docetaxel

RR

Cisplatin

RR

LMP776

RR

LMP400

RR

MDAacq DMSO

0.4 ± 0.2

4.3

22.0 ± 9.9

1.0

62.8 ± 13.7

1.1

8.9 ± 11.7

5.0

10.5 ± 9.7

1.2

MDAacq

1.7 ± 0.3

21.0 ± 5.3

70.6 ± 4.1

44.6 ± 45.7

12.4 ± 12.2

MCF-7acq DMSO

0.9 ± 0.5

1.9

20.4 ± 2.3

1.3

26.1 ± 9.5

2.5

a

 

a

 

MCF-7acq

1.7 ± 0.9

25.8 ± 8.2

65.6 ± 53.4

a

a

MDAde novo DMSO

5.2 ± 3.2

3.4

18.0 ± 3.7

1.5

34.7 ± 7.03

2.7

11.0 ± 6.2

2.0

15.8 ± 6.3

1.6

MDAde novo

17.6 ± 1.4

27.3 ± 2.1

95.1 ± 4.9

22.5 ± 4.3

25.8 ± 3.5

MCF-7de novo DMSO

8.1 ± 9.1

1.2

24 ± 7.5

1.5

45.6 ± 5.4

1.2

40.0 ± 14.2

1.4

42.6 ± 36.3

1.4

MCF-7de novo

10.0 ± 7.9

34.9 ± 10.2

53.7 ± 13.0

55.9 ± 28.6

58.2 ± 36.5

  1. Mean IC50-value (μM) ± standard deviation of three independent experiments. RR; relative resistance is the IC50-value of the resistant cell line divided by the IC50-value of their corresponding DMSO controls aCross-resistance by looking at the graphs as 50 % inhibition was not achieved with these drugs